Use of wipes with emollient and barrier properties for the prevention of pressure injuries: a multicentre randomised controlled trial Authors: Hayley Ryan, Peta Ellen Tehan, Oya Gumuskaya, Alison Hutton, Brett Mitchell Published: 2026 ABSTRACT AbstractObjectiveTo evaluate the effectiveness of a twice-daily application of a wipe impregnated with emollient and barrier ingredients in reducing incidence of pressure injury (PI) in aged care consumers.DesignA single-blinded, multicentre randomised controlled trial. Randomisation was stratified by facility, using simple 1:1 randomisation within each stratum.Setting20 residential aged care facilities in Rural and Metropolitan New South Wales and the Australian Capital Territory, Australia.Participants858 aged care consumers aged ≥65 years at risk of developing a PI.InterventionParticipants were randomised 1:1 to receive either standard hygiene practices, repositioning and use of pressure redistribution surfaces (standard care) or twice-daily applications of a pre-packaged wipe impregnated with emollient and barrier ingredients (Contiplan) to the sacrum, buttocks and heels in addition to standard care for the study duration.Primary outcome and analysisThe primary outcome was the incidence of PIs per 1000 consumer days. Treatment effects were estimated using an intention-to-treat approach, with the absolute difference and 95% CI estimated using the Wald method. The relative difference in the incidence of PIs was estimated using a negative binomial regression model (with log link).Results858 participants were included in the study. There was a 50% relative reduction in the incidence of PI in the intervention compared with the control (95% CI 0.31 to 0.81, p=0.005), with an absolute rate difference of 0.31 fewer PIs per 1000 consumer days (95% CI 0.11 to 0.51).ConclusionThe use of wipes with emollient and barrier properties significantly reduced the incidence of PIs and prolonged the time to first PI, demonstrating efficacy as a PI preventive strategy in aged care.Trial registrationAustralian and New Zealand Clinical Trials Registry, ACTRN12622001360707.Keywords: Barrier preparations, Moisturiser, Emollients, Pressure injuries, Skincare STRENGTHS AND LIMITATIONS OF THIS STUDY This study was a multicentre, single-blinded randomised controlled trial conducted across 20 residential aged care facilities in both rural and metropolitan regions of Australia. This study was a multicentre, single-blinded randomised controlled trial conducted across 20 residential aged care facilities in both rural and metropolitan regions of Australia. The intervention was standardised using pre-packaged, pH-neutral wipes, which improved reproducibility and fidelity. The intervention was standardised using pre-packaged, pH-neutral wipes, which improved reproducibility and fidelity. Intervention fidelity was monitored through documented product usage and staff reporting. Intervention fidelity was monitored through documented product usage and staff reporting. Limitations included the inability to double blind the delivery of the intervention. Limitations included the inability to double blind the delivery of the intervention. Introduction Pressure injuries (PIs), also known as pressure ulcers or bedsores, are localised skin and soft tissue injuries caused by sustained pressure and shearing forces, often compounded by factors such as poor nutrition, comorbidities and poor skin condition.1 These injuries disproportionately affect vulnerable populations, particularly older adults in long-term care, with prevalence rates ranging from 8.8% to 53.2% and incidence rates varying from 7% to 71.6%.1 Despite preventative strategies such as repositioning and pressure offloading, PIs remain a significant cause of morbidity, leading to increased hospital admission, prolonged hospital stays, increased healthcare costs and premature mortality.2 The multifactorial nature of PIs complicates the development of universally effective prevention methods, highlighting the need for additional interventions.3 Maintaining adequate skin hydration is critical for skin integrity and PI prevention, particularly in high-risk individuals.4 Previous studies have demonstrated that older people in aged care facilities with skin dryness had a greater than two-fold increased odds of developing a stage 2+PI.5 Barrier preparations are proposed to enhance epidermal hydration and resilience, thereby strengthening the skin’s tolerance against friction and shear forces and reducing the risk of pressure related tissue damage.6 This mode of action supports the concept of the enhancement of skin integrity as an indirect prevention strategy for PIs.7 While stratum corneum hydration has been investigated as a potential predictor of early skin breakdown, the association with the development of PI remains unclear.4 However, the 2019 International Guideline on the Prevention and Treatment of Pressure Ulcers/Injuries identifies clinically relevant skin dryness as a recognised risk factor for reduced skin tolerance to pressure and shear.3 This highlights the importance of the assessment of skin integrity, the adoption of skin prevention strategies and the potential role of optimising skin hydration in at-risk populations.5 Whilst guidelines acknowledge the importance of good skin integrity to prevent PI,3 the evidence on the effectiveness of different interventions to improve skin quality in order to prevent PI is lacking. A recent systematic review on dressings and topical agents for PI prevention concluded that while some topical preparations show potential, the overall certainty of evidence remains low.8 Another recent systematic review and meta-analysis found limited evidence from randomised controlled trials (RCT) on the efficacy of moisturisers, emollients or barrier preparations in preventing PIs.8 Therefore, quality trials are needed in this area. In addition to pressure injury prevention, incontinence-associated dermatitis (IAD) is another important skin complication in aged care residents. IAD is an irritant contact dermatitis which results from prolonged exposure of the skin to urine and/or faeces,9 estimated to impact up to 21% of nursing home residents.10 Preventative strategies such as barrier products are commonly recommended; however, a recent systematic review of skin cleansers and leave-on products for prevention of IAD highlighted that although barrier preparations may reduce IAD incidence, the certainty of evidence is low and further high-quality trials are required.11 This study therefore aimed to evaluate the effectiveness of twice-daily application of a wipe with emollient and barrier properties in reducing PI incidence among at-risk individuals in aged care settings. The study also aimed to evaluate the effectiveness of the intervention for reducing IAD incidence (as an exploratory secondary outcome). Methods Trial design This was a single-blinded, multicentre randomised controlled trial (RCT). Researchers conducting the statistical analysis were blinded to the participant group allocation. The trial was conducted over 8 months (from 1 November 2023 to 30 June 2024) across 20 residential aged care facilities (RACFs) in Rural and Metropolitan New South Wales and the Australian Capital Territory, Australia (Australian and New Zealand Clinical Trials Registry Number: ACTRN12622001360707). The clinical trial protocol is provided in the online supplemental material. The RACFs were selected based on their comparable demographic profiles and standardised models of care delivery for PI prevention and management. An expression of interest was sent to 76 RACFs within a large aged care provider, with 20 facilities subsequently participating. There was a need to limit to 20 facilities in the interest of feasibility. Priority was given to those with similar geographical locations to maintain consistent environmental factors. The number of participants enrolled at each facility, with breakdown by intervention and control, is shown in online supplemental table S4. bmjopen-16-5-s001.pdf bmjopen-16-5-s002.pdf Participants Eligible participants were recruited from the enrolled RACFs. The inclusion criteria for the study were: 65 years or older at the time of consent, permanently residing in a RACF, and having limited mobility, defined as the ability to stand and pivot during transfers. Additionally, participants must have been able to provide informed consent, or consent was obtained from a legal guardian. Those at risk for PIs as defined by Waterlow scores of 10 or higher12 were also included in the study. Variation in recruitment numbers across facilities reflected differences in facility size (small 40-bed to large 120-bed RACFs), resident case-mix and the number of residents meeting eligibility criteria (limited mobility, Waterlow≥10, no existing PI/IAD). Exclusion criteria included individuals under the age of 65, those with a current PI on the heels, buttocks or sacrum, or current IAD, as the wipes with emollient and barrier properties cannot be applied to active wounds. Participants not living in an enrolled RACF or those with allergies or sensitivities to any of the ingredients in the wipes with emollient and barrier properties were excluded. Also excluded were individuals who were fully mobile, able to weight-bear and walk more than a metre, due to their very low risk for PIs or IAD. Those receiving respite care rather than permanent residency in the RACF, as well as individuals who were palliative or considered at the end of life, were also not eligible for the study. Full inclusion and exclusion criteria are detailed in online supplemental table S1. Eligibility screening was conducted by the aged care facility nursing staff, who were independent of the research team who were responsible for randomisation and outcome assessment. The nursing staff did not have access to the secure web-based randomisation system and could not view or predict future allocations. Allocation concealment was therefore fully maintained throughout recruitment. Intervention The intervention involved the twice-daily application of a pre-packaged non-woven wipe impregnated with emollient and barrier ingredients (Contiplan, GAMA Healthcare Australia; key ingredients and specifications are provided in online supplemental table S2) to participants’ heels, sacrum and buttocks. The barrier wipe formulation contains key functional ingredients designed to protect and hydrate aged skin. Primary components include water; glycerin (humectant); dimethicone (barrier protectant); aloe vera extract (soothing agent); and panthenol (skin conditioner). The formulation also contains mild surfactants suitable for fragile skin. The product is fragrance-free, dermatologically tested for aged skin and manufactured with a reported pH of 7. Care staff applied the wipes following morning hygiene care and before bedtime, using a new wipe for each body area and allowing the skin to air dry. Both groups received standard facility care, which included routine hygiene practices (soap-free cleansers and incontinence pads as required), repositioning and use of pressure redistribution surfaces, consistent with facility protocols and international guidelines. All care staff received structured training via videoconference by the lead researcher (HR), covering best practice application technique, infection control, designated areas of use and disposal methods. Refresher training sessions were conducted monthly, and compliance was monitored weekly by deputy service managers at each facility, with usage recorded. A complete description of the intervention according to the TIDieR checklist is provided in online supplemental table S7. Outcomes and data collection The primary outcome was the incidence of PIs per 1000 consumer days. This outcome corresponds to the incidence of PIs over time as specified in the trial protocol, the reporting scale was expressed as incidence per 1000 consumer-days, rather than per resident-year, to account for variable follow-up duration across participants and facilities. In the study protocol, this rate-based outcome was expressed as incidence per resident-year, in the final report, it is presented as incidence per 1000 consumer-days, which is an equivalent epidemiological metric that provides clearer accounting of individual follow-up time. Secondary outcomes were the incidence of IAD and the time (in days) to first PI and time to first IAD event. IAD was collected as an exploratory secondary outcome. Baseline data were collected for all participants, including demographic information and the RACF location, categorised as rural or metropolitan based on the Modified Monash Model.13 Outcome assessments were conducted by facility nursing staff, who were not blinded to group allocation. To minimise misclassification, staff received structured training in PI and IAD recognition, supported by standardised staging tools (National Pressure Injury Advisory Panel (NPIAP) categories and the GLOBIAD framework). Data analysis was performed blinded to group allocation. An overview of the data collection processes, timing and sources is provided in online supplemental table S3. Daily assessments for PIs in facilities were prospectively conducted by care staff as part of standard practice through routine skin evaluations.14 Registered nurses and care staff examined high-risk areas, including heels, sacrum and buttocks, for skin breakdown. If redness was observed, immediate offloading and pressure redistribution were initiated, and the Registered Nurse performed further assessment in accordance with international guidelines.15 PI severity was not considered a separate outcome; rather, all identified PIs were staged at the time of assessment according to the NPIAP classification system (Stage 1–4, unstageable or deep tissue pressure injury).15 Severity (stage) was recorded descriptively as a characteristic of each pressure injury event and used to describe the distribution of injury severity between groups. These charts recorded wound characteristics, treatment progress and healing outcomes. If a PI or IAD occurred, the date and anatomical location, IAD classification and PI staging were collected (online supplemental table S3). The validated PI staging system ensured consistent categorisation based on specific characteristics, while the Ghent Global IAD (GLOBIAD) tool classified IAD severity.16 For each participant, the number of PIs was obtained directly from facility wound documentation, which was completed by nursing staff as part of routine care using standardised PI and IAD assessment tools. Follow-up time for each participant commenced at the date of study enrolment and continued until study cessation, defined as the earliest occurrence of study completion, transfer to hospital or another facility, death or withdrawal from the study. Consumer-days were calculated individually for each participant over this follow-up period. The incidence of PIs per 1000 consumer-days was calculated by dividing the total number of PI events by the total accumulated consumer-days within each treatment group. Time-to-event outcomes (time to first PI and time to first IAD) were defined as the number of days from study enrolment to the date of the first documented event. Participants who did not experience a PI or IAD were censored at the date of study cessation (study completion, transfer, death or withdrawal), consistent across both outcomes. The fidelity of the intervention was assessed by recording both the distribution and actual use of the barrier wipes. These data were compared against the calculated minimum requirement for twice-daily application to evaluate compliance with the study protocol. Sample size The sample size calculation was based on expected incidence rates of PIs in Australian residential aged care17, reporting an incidence rate of 1.33 PIs per 1000 resident-days, equivalent to 0.49 events per resident-year or 0.33 events over an 8-month period. This value was therefore used as the expected baseline incidence rate. Evidence from prior studies of prophylactic barrier products and sacral/heel dressings has demonstrated reductions in PI incidence ranging from 30% to 50%.18 19 A 40% relative reduction (from 0.33 to 0.196 events per 8 months) was therefore selected as a conservative, evidence-informed effect size. The sample size was calculated for comparing two incidence rates using a two-sided test with α=0.05 and 80% power. A sample of 330 participants per group was required to detect a reduction from 0.33 to 0.196 events over 8 months. Allowing for an anticipated 30% attrition rate, the required sample size increased to 429 participants per group (total n=858). This approach aligns with the primary outcome definition (incidence per 1000 consumer-days), and the full numerical derivation has been added to allow replication. Randomisation Participants were randomised in a 1:1 ratio to the intervention or control group, stratified by facility to account for potential differences in resident characteristics and care practices across sites. Stratification by facility was introduced prior to the commencement of recruitment and before any randomisation occurred, to ensure balance across facilities of varying size and resident case-mix. Within each facility, simple randomisation was used without blocking. The random allocation sequence was generated by an independent investigator (BM) using IBM SPSS Statistics V.29. Separate computer-generated randomisation schedules were created for each facility. Allocation concealment was maintained via a secure web-based system accessible only to two researchers (HR and BM). The outcome assessor did not have access to the allocation system. Although stratification by facility was not explicitly described in the original trial protocol, it was implemented prior to participant enrolment and before any randomisation occurred, following consultation with the trial statistician, as an operational refinement to ensure balance across facilities of differing size and resident case-mix. Statistical methods The proposed null hypothesis was that the use of wipes does not increase or prevent the incidence of a PI. All analyses were conducted using IBM SPSS Statistics (V.29).20 Baseline characteristics were summarised descriptively. An intention-to-treat analysis was used for the primary outcome of the incidence of PIs per 1000 consumer days. A per-protocol analysis was not prespecified in the trial protocol and is not presented, in accordance with Consolidated Standards of Reporting Trials (CONSORT) guidance. The intention-to-treat analysis represents the primary estimate of interest. We included all participant data in the study, regardless of whether they completed the trial or not. In accordance with CONSORT recommendations, no statistical testing of baseline characteristics was performed. The absolute difference and 95% CI were estimated using the Wald method. The relative difference in the incidence of PIs was estimated using a negative binomial regression model (with log link). The model included group and study site as independent variables and log of the days in study as an offset. We reported the exponentiated coefficients for group with 95% Wald CIs. The adjusted negative binomial regression model was specified as the primary analysis for estimating the relative treatment effect as a complementary descriptive measure to aid interpretation. This estimate was calculated from the observed event rates (events per person-time) in each group with a Wald CI based on the variance of the difference in rates, which incorporates follow-up time through the person-time denominators. Time to first event outcomes (first PI or IAD) were described using Kaplan-Meier survival curves. A Cox proportional hazards model was developed to estimate the hazard of the first PI or IAD (binary outcome), comparing intervention and control groups. To assess the robustness of the primary outcome to potential site-level influence, a leave-one-site-out sensitivity analysis was performed. This analysis was conducted for the primary outcome (incidence of PIs per 1000 consumer-days) by sequentially excluding one facility at a time and recalculating incidence rates, rate differences and comparing each arm using the Wald method. Consistency of the treatment effect across exclusions was used to assess whether the primary findings were driven by any single site. Patient and public involvement None. Results Between 1 November 2023 and 30 June 2024, a total of 858 participants commenced the study, with 636 completing the study (figure 1). Consumer enrolment and analysis flowchart. The mean age of all participants was 86 years (SD 8). An equal number of participants were randomised to standard care or the intervention (n=429 in both groups). Table 1 provides a summary of the participant characteristics and risk factors. Table 1Demographic and clinical characteristics of the study cohortCharacteristicControl(n=429)Intervention(n=429)TotalSex Male, n (%)143 (33)145 (34)288 Female, n (%)286 (67)284 (66)570Age Mean (SD)86 (SD 8)87 (SD 7)86 (SD 8)Location Metropolitan, n (%)316 (74)313 (73)629 Rural, n (%)113 (26)116 (27)229Withdrawals Did not withdraw, n (%)322* (75)314* (73)636 Deceased, n (%)107* (25)111* (26)218 Transferred, n (%)0* (0)2* (<1)2 Withdrew voluntarily, n (%)0* (0)2* (<1)2Waterlow score Mean (SD)21 (6)21 (6)21 (6)Waterlow risk level At risk (10+)79† (18)82† (19)161 High risk (15+)114† (27)110† (26)224 Very high risk (20+)236† (55)237† (55)473Support surface in place Yes, n (%)429 (100)429 (100)858 No, n (%)0 (0)0 (0)0Type of support surface Air mattress87‡ (20)75‡ (17)162 Alternating mattress146‡ (34)140‡ (33)286 Bed cradle17‡ (4)20‡ (5)37 Heel lift boot4‡ (<1)2‡ (<1)6 Memory foam mattress128‡ (30)147‡ (34)275 ROHO47‡ (11)45‡ (10)92Days in RACF before study commencement Mean (SD)1109 (1183)1033 (980)1071 (1087)Total number of days in study, n (%) Total days in study 89 13587 636176 771Mean (SD)208 (71)204 (76)206 (73)Note.1 Support mattress means any surfaces required to alleviate pressure such as an air mattress, alternating mattresses, bed cradle, heel lift boot, memory foam mattress or ROHO (seat pressure redistribution cushion) cushion. Metropolitan or rural location was determined by the Modified Monash Model (MM7) (Australian Government Department of Health, 2019).*Indicates the percentage of those individuals in a particular treatment group which had not withdrawn from the study or who had become deceased, transferred out of the facility or who withdrew.†Indicates the percentage of those individuals in a particular treatment group which had Waterlow scores by risk category.‡Indicates the percentage of those individuals in a particular treatment group which had each type of support surface in place.RACF, residential aged care facilities. Demographic and clinical characteristics of the study cohort Note.1 Support mattress means any surfaces required to alleviate pressure such as an air mattress, alternating mattresses, bed cradle, heel lift boot, memory foam mattress or ROHO (seat pressure redistribution cushion) cushion. Metropolitan or rural location was determined by the Modified Monash Model (MM7) (Australian Government Department of Health, 2019). *Indicates the percentage of those individuals in a particular treatment group which had not withdrawn from the study or who had become deceased, transferred out of the facility or who withdrew. †Indicates the percentage of those individuals in a particular treatment group which had Waterlow scores by risk category. ‡Indicates the percentage of those individuals in a particular treatment group which had each type of support surface in place. RACF, residential aged care facilities. Baseline characteristics were broadly similar between groups, as expected with randomisation. All participants had an appropriate pressure support surface in place. The total consumer days under observation in the study was 176,771, with 89 135 in the control group and 87 636 in the intervention group. Pressure injury outcomes There were 82 PIs recorded across both groups during the study period. Two participants had two PIs develop during the trial period, with no participants developing more than two PIs. Among the 429 participants in the control group, 55 (13%, 95% CI 9.8 to 16.6) developed a PI in the control group (n=429), compared with 27 (6%, 95% CI 4.2 to 9.0) in the intervention group. There was a 50% relative reduction in the incidence of PI in the intervention compared with the control 95% CI 0.31 to 0.81, p=<0.01. The incidence of PIs per 1000 consumer days was also significantly lower in the intervention group (0.31) compared with the control group (0.62), with an absolute rate difference of 0.31 fewer PIs per 1000 consumer days (95% CI 0.11 to 0.51). Regarding the severity of PI, there were significantly more participants with a Stage two pressure injury in the control group (6%), compared with the intervention (1%), p<0.01 (table 2). Table 2Pressure injury incidence and severity in the intervention and control groupsPressure injury characteristicControl(n=429)Intervention(n=429)All(n=858)P valueNo, n (%)374 (87)402 (94)776 (90)<0.01Yes, n (%)55 (13)27 (6)82 (10)Stage I, n (%)23 (5)20 (5)43 (5)0.6Stage II, n (%)25 (6)5 (1)30 (3)<0.01Stage III, n (%)1 (<1)0 (<1)1 (<1)–Stage IV, n (%)1 (<1)0 (<1)1 (<1)–SDTI, n (%)5 (1)2 (<1)7 (<1)0.267Unstageable0 (0)0 (0)0 (<1)–Left buttock, n (%)0 (0)1 (<1)1 (<1)–Right buttock, n (%)0 (0)0 (0)0 (<1)–Left heel, n (%)9 (2)5 (1)14 (2)–Right heel, n (%)6 (1)3 (<1)9 (1)0.6Sacrum, n (%)40 (9)18 (4)58 (14)0.6Incidence per 1000 consumer days (95% CI)0.62(0.47 to 0.80)0.31(0.20 to 0.45)<0.01Incidence absolute difference per 1000 consumer days rate (95% CI)0.31 (0.11 to 0.51)Incidence relative risk difference per 1000 consumer days (95% CI)0.50 (0.31 to 0.81)Note. * p<0.05.*Indicates the χ2 test was run on only No PI, Stage I and Stage II, due to expected counts for the other categories being below 5, violating the assumption of the χ2 test of independence.†Indicates the χ2 test was run on only No IAD and Cat 1a IAD, due to expected counts for the other categories being below 5, violating the assumption of the χ2 test of independence.IAD, incontinence-associated dermatitis; PI, pressure injury; SDTI, suspected deep tissue injury. Pressure injury incidence and severity in the intervention and control groups Note. * p<0.05. *Indicates the χ2 test was run on only No PI, Stage I and Stage II, due to expected counts for the other categories being below 5, violating the assumption of the χ2 test of independence. †Indicates the χ2 test was run on only No IAD and Cat 1a IAD, due to expected counts for the other categories being below 5, violating the assumption of the χ2 test of independence. IAD, incontinence-associated dermatitis; PI, pressure injury; SDTI, suspected deep tissue injury. The anatomical distribution of PIs was similar between groups, with the sacrum being the most common site (n=58) followed by the heels (n=23). Further detail on the frequency of PIs by stage and anatomical location is provided in online supplemental table S5. The leave-one-site-out sensitivity analysis demonstrated that the treatment effect on pressure injury incidence remained consistent when each facility was sequentially excluded, indicating that the primary findings were not driven by any single site (online supplemental table S6). Secondary outcomes Incontinence-associated dermatitis There were 21 cases of IAD in the intervention group and 31 cases of IAD in the control group (table 3). Table 3Incontinence-associated dermatitis (IAD) outcomes in the intervention and control groupsCharacteristicsControl(n=429)Intervention(n=429)All(n=858)P valueNo IAD, n (%)397 (93)408 (95)805 (94)0.1IAD, n (%)32 (7)21 (5)53 (6)Category 1a, n (%)27 (6)20 (5)47 (5)0.3Category 1b, n (%)4 (<1)0 (<1)4 (<1)Category 2a, n (%)1 (<1)1 (<1)2 (0.23)Category 2b, n (%)0 (0)0 (0)0 (0)Incidence per 1000 beddays (95% CI)0.36(0.25 to 0.51)0.24(0.15 to 0.37)0.1Time to first IAD (days), median (95% CI)106.0 (81.3 to 130.6)142.1 (113.0 to 171.3)120.3 (101.0 to 139.6)0.06 Incontinence-associated dermatitis (IAD) outcomes in the intervention and control groups The incidence of IAD per 1000 consumer days was lower in the intervention group (0.24; 95% CI 0.15 to 0.37) compared with the control (0.36; 95% CI 0.25 to 0.51), but the difference was not statistically significant (p=0.1; table 3). The difference between the two groups was 0.11 per 1000 consumer days (95% CI 0.05 to 0.27). In terms of IAD severity, the most common category was Category 1a, affecting 47 participants (5.5%), with fewer cases observed in the intervention group (n=20 40.7%) compared with the control group (n=27, 6.3%). Time to first PI At 120 days, 91.6% of the control group had not developed PI, whereas 97.4% in the intervention group had not developed PI. The Kaplan-Meir survival distribution is displayed in figure 2. The instantaneous risk of developing a PI during follow-up was approximately 50% lower in the intervention group compared with the control group (HR=0.47, 95% CI 0.29 to 0.74, p=<0.01). Time to first pressure injury. Time to first IAD At 120 days, 95.6% of the control group remained IAD free, whereas 98.1% of the intervention group were IAD free (figure 3). There was no significant difference in time to first IAD in the intervention group, 142.1 days (95% CI 113.0 to 171.3), compared with the control 106.0 days (95% CI 81.3 to 130.6; p=0.064). The difference in instantaneous risk of IAD in the trial period between groups was not statistically significant (HR: 0.64, 95% CI 0.37 to 1.11, p=0.11). Time to first Incontinence-associated dermatitis. Intervention fidelity The fidelity of the barrier wipes was maintained throughout the study, ensuring consistent application as per protocol. In terms of product usage, the total number of wipes used in the intervention group was 525 432 wipes (21 017 packets). These data support the reliability of intervention implementation and adherence. Discussion This study aimed to determine whether the twice-daily use of a wipe impregnated with emollient and barrier ingredients could reduce the incidence of PIs and IAD in aged care consumers. The findings demonstrate a significant reduction in PI incidence and increased time to initial PI onset. While a lower incidence of IAD was also observed in the intervention group, this finding was not statistically significant and should be interpreted with caution as this outcome was exploratory. These results are clinically relevant, supporting the integration of wipes impregnated with emollient and barrier ingredients as an effective strategy for PI prevention in aged care settings. Skin care has long been considered an integral part of pressure injury prevention,21 with the cleansing, hydration and protection of skin from excess moisture recommended in current guidelines.3 The wipes used in the current trial perform all three of these actions: cleansing, hydration and protection. Therefore, the mechanisms by which wipes may reduce PI incidence are likely multifaceted. Cleansing of the skin results in improved hygiene by reducing microorganisms and the build up of potential irritants.22 The specific ingredients of the wipes may also play a role. Dimethicone reduces trans-epidermal water loss and has been demonstrated to have skin protective effects23; humectants such as glycerin enhance skin hydration24; panthenol improves epidermal barrier function and stratum corneum hydration25; aloe vera has anti-erythema effects.26 Skin care can maintain or improve skin integrity which may result in an increased ability to tolerate pressure,27 28 which may explain the reduction in observed PIs. Skin focused preventative strategies have been heavily researched in recent years, with varying degrees of quality. Two recent systematic reviews have investigated the use of skin care preparations to prevent PI. A systematic review and meta-analysis by Ryan et al8 showed that moisturisers, emollients and barrier preparations did not significantly reduce the incidence of pressure injury (relative risk 0.50, 95% CI 0.15 to 1.63). However, it was noted that there was a substantial lack of quality RCTs, limited available data, and unclear risk of bias. Additionally, Patton et al28 conducted a systematic review evaluating dressings or topical agents for PI prevention. Patton et al28 concluded that while silicone dressings and fatty acid preparations showed potential benefit, the overall evidence was of low certainty due to inconsistent methodologies and high risk of bias. Fatty acid preparations include agents such as olive oil (oleic acid) which are proposed to form a thin film on the epidermis, resulting in accelerated epidermal proliferation resulting in improved skin hydration29 and maintaining skin integrity.30 Another proposed mechanism behind PI prevention with olive oil is the phenolic compounds which modulate early inflammatory responses, thereby delaying tissue damage.31 A systematic review by Lin et al demonstrated that olive oil and sweet almond oil can help delay the incidence of PI,32 consistent with the delay in incidence seen in the current study. While potentially beneficial, the manual application of olive oil may be impractical in clinical settings and could therefore reduce adherence. The current study explored a pre-packaged wipe as a more feasible and scalable alternative, particularly in aged care settings where a simple and efficient application method may support better adherence and integration into routine care. The results of the current study are also similar to previous studies which investigated the use of barrier preparations to prevent PI in aged care settings. A retrospective study in 57 participants by Clever et al33 investigated the use of a barrier cream product to prevent sacral pressure injury in aged care consumers. While the study showed favourable effects, the results were not statistically significant in decreasing PI incidence. In contrast to the current study, the study by Clever et al33 was not sufficiently powered and did not include heel PIs. The results of the current study are more similar to a quasi-experimental study by Hunter et al34 conducted in two aged care facilities. This study demonstrated that a combination wipe that included barrier preparation and emollient was effective in significantly reducing incidence of PI in 328 aged care consumers. The study by Hunter et al34 included the intervention as part of a skin care bundle which included a body wash to further support skin hydration. Therefore, a multifaceted approach to the care of the skin that considers cleansing as well as addition of moisture and a barrier preparation may be preferable to the use of a single topical agent in isolation. The key findings of this study highlight the importance of structured skin care protocols in aged care settings. The intervention group experienced a 51% lower incidence of PIs compared with the control group, with extended time to first PI. These results reinforce the role of prophylactic skin care in delaying PI onset, consistent with international guidelines.3 Others have also demonstrated the effectiveness of structured skin care protocols in reducing skin tears35 in aged care settings, with a 50% reduction in skin tears utilising a twice-daily skin moisturising regimen.35 While trials evaluating the use of topical skin care preparations for the prevention of wounds use a variety of different products, the underlying aim of the skin care product is to improve the quality of the skin to tolerate mechanical stress or trauma. IAD is common in older people who experience changes in skin physiology, leading to a weakened skin barrier.36 Friction and shear have also been identified as risk factors for IAD37 38; therefore, it is sensible to extrapolate that improving skin integrity and promoting skin to handle pressure and shear will also assist in reducing the incidence of IAD. In the present study, the reduction in IAD was not statistically significant. The quasi-experimental study by Hunter et al,34 conducted in two aged care facilities, similarly found a reduction in perineal dermatitis as a result of the application of the barrier preparation. The current study applied the product to the buttocks, and not the perineum, which may partially explain the lack of significant difference in outcome. This study has several limitations that should be considered. Stage 1 PIs (localised persistent non-blanchable erythema) were observed across both groups; however, early-stage PI identification is subject to inter-rater variability, particularly in routine clinical settings. This may be a result of uncertain levels of reliability with the inclusion of multiple staff measuring the outcome and is a limitation of the study. Furthermore, there also may have been difficulties identifying erythema in residents with darker skin tones,39 oedema or under variable lighting. Blinding of care staff to the intervention was not possible due to the nature of the product, which may have introduced performance bias. Assessment of the outcomes were conducted by facility nurses within routine care rather than by external blinded research staff. This raises the possibility of detection bias, particularly for early-stage lesions (category 1–2) and sacral skin changes, where misclassification between PI and IAD is widely reported. To mitigate this, participating staff received structured training in PI/IAD recognition, including visual case examples and reference guides based on the International Guideline, and were supported by senior clinicians within each facility. Although IAD diagnoses were based on documented incontinence status, we cannot exclude some degree of misclassification given the overlap in presentation with early-stage PI. Importantly, we did not directly measure skin hydration status, which may have provided further insight into mechanisms behind the effectiveness of the wipe in improving skin quality. Future studies incorporating validated hydration scoring or biophysical skin assessments are warranted. Finally, the trial was conducted in Australian RACFs, which may limit generalisability to other countries or settings. A key strength of this study was its trial design, and high adherence to protocol and fidelity. Additionally, this study was conducted across 20 different rural and metropolitan RACF sites improving generalisability within an Australian setting. The use of a standardised wipe, as opposed to varied topical agents, enhances the reliability and reproducibility of the findings with a consistent volume of product used at every application. Conclusion This RCT evaluated the effectiveness of a wipe with emollient and barrier properties intervention in reducing PI among aged care consumers. The results demonstrate that the twice-daily application of wipes with emollient and barrier properties is a simple and effective preventive strategy for PIs in residential aged care, with the potential to shape clinical guidelines and practices both nationally and internationally. The findings highlight the critical need for clinicians and aged care providers to prioritise prevention and early intervention strategies, particularly for older adults with comorbidities and limited mobility. Future research should explore the economic impact and feasibility of widespread implementation while further investigating IAD prevention. Supplementary Material Reviewer comments Author's manuscript Acknowledgments The authors would like to express gratitude to the participants in the study as well as the management, care and clinical staff at the participating organisation. Footnotes Contributors: HR, BM, PET and OG conceived the study. BM and PET provided critical input into the study design. HR coordinated the intervention, oversaw project administration and led data collection, with support from OG. HR, BM and PET conducted the primary analysis. All authors contributed to interpretation of the data. HR drafted the initial manuscript. BM, PET, AH and OG provided critical revisions for important intellectual content. All authors reviewed and approved the final version of the manuscript. HR is the guarantor of the study. Funding: This work was supported by a PhD scholarship from the University of Newcastle awarded to HR. The wipes used in this study were supplied in-kind by GAMA Healthcare Australia, consistent with the funding information provided on the ANZCTR trial registry. GAMA Healthcare Australia had no role in the study design, data collection, analysis, interpretation of results, manuscript preparation or decision to submit for publication. There is no grant number associated with this support. Competing interests: HR and OG are affiliated with the University of Newcastle, which provided scholarship support to HR. The University of Newcastle had no role in the study design, data collection, analysis, interpretation of results, manuscript preparation or decision to submit for publication. The wipes used in this study were supplied by GAMA Healthcare Australia to HR for use in this study. They had no role in the study design, data collection, analysis, interpretation of results, manuscript preparation or decision to submit for publication. HR reports payments from WoundRescue Pty Ltd. HR reports contracts from wound view steering committee outside of the submitted work. HR reports consulting fees from Wounds Australia and the Australian Government outside of the submitted work. HR reports honourarium GAMA Healthcare Australia, Molnlycke, Smith & Nephew, Coloplast, 3M, Wicking Centre, Team Medical, Alpha Lifecare, South Western Sydney PHN and Nestlé Health outside of the submitted work. PT reports honouraria for their role as Editor-in-Chief of Wound Practice and Research (journal) outside of the submitted work. BM reports funding from the NHMRC, MRFF and GAMA Healthcare (paid to institution) outside of the submitted work. BM reports consulting fees ICS Service Solutions (paid to their institution) outside of this work. BM reports an honourarium for their role as Editor-in-Chief of Infection, Disease and Health from the Australasian College for Infection Prevention and Control. AH reports consultancy from the International Council of Nurses and South Australian Police Force (outside of this submitted work). OG reports no competing interests. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research. Ethics approval and consent to participate: Ethical approval for the study was granted by the University of Newcastle Human Research Ethics Committee (HREC: H-2022-0357) and the Aged Care Organisations Research Committee. Written informed consent was obtained from all cognitively aware participants. For participants lacking capacity, consent was provided by their nominated representatives. Participants’ medical practitioners were notified of the study and screened for any medical contraindications. No allergies to wipe ingredients were identified. Participants who objected to the intervention or who withdrew (due to transfer, death, or voluntary withdrawal) were excluded and documented. For queries relating to this approval, please contact the University of Newcastle Human Research Ethics Office (human-ethics@newcastle.edu.au). Provenance and peer review: Not commissioned; externally peer reviewed. Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. Data availability statement Data are available upon reasonable request. De-identified individual participant data (including all variables collected during the trial), the statistical analysis code, and the full protocol will be made available upon reasonable request to the corresponding author, subject to relevant ethics approvals. Data will be available immediately following publication and for up to 5 years thereafter. Requests will be reviewed on a case-by-case basis by the principal investigator and primary sponsor, and data will be shared for ethically approved research proposals that align with the aims specified in the request. Data availability statement De-identified individual participant data (including all variables collected during the trial), the statistical analysis code, and the full protocol will be made available on reasonable request to the corresponding author, subject to relevant ethics approvals. Data will be available immediately following publication and for up to 5 years thereafter.Requests will be reviewed on a case-by-case basis by the principal investigator and primary sponsor, and data will be shared for ethically approved research proposals that align with the aims specified in the request. De-identified individual participant data (including all variables collected during the trial), the statistical analysis code, and the full protocol will be made available upon reasonable request to the corresponding author, subject to relevant ethics approvals. Data will be available immediately following publication and for up to 5 years thereafter. Requests will be reviewed on a case-by-case basis by the principal investigator and primary sponsor, and data will be shared for ethically approved research proposals that align with the aims specified in the request. Ethics statements Patient consent for publication Not applicable. References Associated Data Supplementary Materials bmjopen-16-5-s001.pdf bmjopen-16-5-s002.pdf Reviewer comments Author's manuscript Data Availability Statement Data are available upon reasonable request. De-identified individual participant data (including all variables collected during the trial), the statistical analysis code, and the full protocol will be made available upon reasonable request to the corresponding author, subject to relevant ethics approvals. Data will be available immediately following publication and for up to 5 years thereafter. Requests will be reviewed on a case-by-case basis by the principal investigator and primary sponsor, and data will be shared for ethically approved research proposals that align with the aims specified in the request. De-identified individual participant data (including all variables collected during the trial), the statistical analysis code, and the full protocol will be made available on reasonable request to the corresponding author, subject to relevant ethics approvals. Data will be available immediately following publication and for up to 5 years thereafter.Requests will be reviewed on a case-by-case basis by the principal investigator and primary sponsor, and data will be shared for ethically approved research proposals that align with the aims specified in the request. De-identified individual participant data (including all variables collected during the trial), the statistical analysis code, and the full protocol will be made available upon reasonable request to the corresponding author, subject to relevant ethics approvals. Data will be available immediately following publication and for up to 5 years thereafter. Requests will be reviewed on a case-by-case basis by the principal investigator and primary sponsor, and data will be shared for ethically approved research proposals that align with the aims specified in the request.